Global Insulin Delivery Devices Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Insulin Delivery Devices Market is presumed to reach the market size of nearly USD 44.73 BN by 2030 from USD 20.12 BN in 2022 with a CAGR of 10.5% under the study period of 2023 - 2030. Regarding volume, the market was calculated XX Thousand Units in 2022 and forecast to touch XX Thousand Units by 2030 with a CAGR of XX% during 2023-2030.

Insulin delivery devices are employed for the purpose of administering insulin to individuals diagnosed with diabetes. Insulin, a hormone, is produced by the pancreas that regulates blood sugar levels. In people with diabetes, the body either does not produce enough insulin (Type 1 diabetes) or does not effectively use the insulin produced (Type 2 diabetes). Insulin therapy is essential for managing diabetes and maintaining optimal blood glucose control.

MARKET DYNAMICS:

The increasing prevalence of diabetes worldwide is a key driver, as more individuals are diagnosed with diabetes and require insulin therapy. Innovative insulin delivery devices with features like accurate dosing, improved usability, connectivity, and data tracking capabilities have enhanced convenience and treatment outcomes. The adoption of insulin pump therapy is on the rise, thanks to improved pump designs, ease of use, and better reimbursement policies. Patient comfort and convenience are becoming increasingly important, leading to the development of devices that minimize pain, offer discreetness, and simplify insulin administration processes. Awareness and education about diabetes management, insulin therapy, and the benefits of insulin delivery devices have increased, contributing to their wider acceptance and adoption. Supportive government policies and reimbursement systems further stimulate market growth by promoting access to insulin therapy. The ageing population, coupled with lifestyle changes such as sedentary lifestyles and unhealthy eating habits, has resulted in a higher prevalence of diabetes. This demographic shift and lifestyle factors contribute to the increasing demand for insulin delivery devices.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of insulin delivery devices. The growth and trends of Insulin Delivery Devices Industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the insulin delivery devices market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Pers (Reusable Pens, Disposable Pens)
Pumps (External/ Tethered Pumps, Patch Pumps)
Pen Needles (Standard Pen Needles, Salety Pen Needles)
Syringes
Other Devices

By End User

Patients/Homecare
Hospitals & Clinics

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Insulin Delivery Devices market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the insulin delivery devices market include Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plo (Ireland), Animas Corporation (U.S.), Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Biocon Ltd. (India). Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112111556

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INSULIN DELIVERY DEVICES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By End User
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL INSULIN DELIVERY DEVICES MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Pers (Reusable Pens, Disposable Pens) Historic and Forecast Sales by Regions
5.5 Pumps (External/ Tethered Pumps, Patch Pumps) Historic and Forecast Sales by Regions
5.6 Pen Needles (Standard Pen Needles, Salety Pen Needles) Historic and Forecast Sales by Regions
5.7 Syringes Historic and Forecast Sales by Regions
5.8 Other Devices Historic and Forecast Sales by Regions

6 . GLOBAL INSULIN DELIVERY DEVICES MARKET ANALYSIS BY END USER

6.1 Overview by End User
6.2 Historical and Forecast Data
6.3 Analysis by End User
6.4 Patients/Homecare Historic and Forecast Sales by Regions
6.5 Hospitals & Clinics Historic and Forecast Sales by Regions

7 . GLOBAL INSULIN DELIVERY DEVICES MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE INSULIN DELIVERY DEVICES COMPANIES

8.1. Insulin Delivery Devices Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF INSULIN DELIVERY DEVICES INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Becton
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Dickinson and Company (U.S.)
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Novo Nordisk A/S (Denmark)
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Ypsomed Holding AG (Switzerland)
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Medtronic plo (Ireland)
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Animas Corporation (U.S.)
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Tandem Diabetes Care Inc. (U.S.)
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Sanofi (France)
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Biocon Ltd. (India).
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Eli Lilly and Company (U.S.)
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Insulet Corporation (U.S.)
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies